Lunai Bioworks Inc. LNAI
1.93
(0.01)
(0.52%)
as of 25 Sep
- Market cap
- $8.8M
- P/E
- 0.0×
Follow LNAI
Growth Flags
show if company had growth for consecutive years
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 0.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (9.92) | |
P/B ratio |
— | — | — | 0.00 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 0.00 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (1.47) | |
EV/FCF |
— | — | — | (1.47) | |
Quick Ratio |
0.02 | 0.03 | 0.02 | 0.16 | |
Current Ratio |
0.04 | 0.04 | 0.03 | 0.19 | |
Net Debt/EBITDA |
0.12 | 0.19 | 0.28 | 2.28 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.01 | (0.48) | 0.60 | 0.40 | |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 76.08% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 6,800.48% | |
Intangible Assets out of Total Assets |
0.74 | 0.88 | 0.92 | 0.62 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 808.61% | |
Graham Net Nets |
— | — | — | (1.54) | |
Graham Number |
— | — | — | 64.82 | |
Earnings Yield |
— | — | — | (1,873.48%) | |
Free Cash Flow Yield |
— | — | — | (51.92%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.88) | (0.48) | (0.36) | (0.33) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.88) | (0.48) | (0.37) | (0.33) | |
Cash per Share |
0.23 | 0.22 | 0.17 | 1.01 | |
Shareholders Equity per Share |
(10.35) | (4.63) | (4.62) | (3.06) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(10.35) | (4.63) | (4.62) | (3.06) | |
Free Cash Flow |
(1.81) | (1.35) | (1.07) | (1.03) | |
Working Capital |
(28.11) | (18.92) | (19.49) | (15.55) | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
(28.53) | (19.20) | (19.70) | (15.68) | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (12,303.35%) | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
11.00 | 11.75 | 11.64 | 12.20 | |
Average Assets |
85.68 | 64.40 | 59.00 | 63.79 | |
Average Common Equity |
55.31 | 42.52 | 34.26 | 39.42 |
Columns are period end dates